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Abstract Indirubin derivatives and analogs comprise a sig-
nificant group of ATP-competitive inhibitors. The inhibitory
effects of ChEMBL474807 (1-(4-amino-1,2,5-oxadiazol-3-
yl)-5-(piperidin-1-ylmethyl)-N′-(pyridin-4-ylmethylene)-1H-
1,2,3-triazole-4-carbohydrazide) on two enzymes, namely
glycogen synthase kinase-3β (GSK-3β) and cyclin-
dependent kinase-2 (CDK-2), were analyzed. The close re-
semblance of the amino acid sequences of these two enzymes
(with 25 % identity and 41 % similarity) explains why
indirubin derivatives are inhibitors of both of the enzymes
studied. The docking and molecular dynamics investigation
performed here led to the identification of the interactions
responsible for stabilizing the ligand ChEMBL474807 at the
active sites of the enzymes considered. The structural and
energetic data collected during our investigations clearly indi-
cate that there are important differences in the behavior of the
ligand at the two active sites investigated here.
Keywords ATPase . Competitive inhibition . Similarity .
Molecular dynamics . CDK-2 . GSK-3β
Introduction
Indirubin is a component of Indigo naturalis, namely the red-
colored 3,2′-bisindole isomer. It is an active ingredient used in
a traditional Chinese medicine for the treatment of chronic
diseases. Small bioactive molecules that inhibit cellular repli-
cation machanisms are currently being exploited for novel
therapeutics. Indirubin derivatives such as indirubin-3′-oxime
have been investigated in this respect. Multiple effects of
indirubin-3′-oxime on the activity of mitochondrial ATPase
have been observed, indicating that this small molecule inter-
feres with cell function [1]. Studies performed in vitro and on
animals have shown that indirubin and its derivatives possess
anti-inflammatory [2], antitumor [3, 4], antiangiogenic [5],
and neuroprotective [6] effects. They also inhibit cyclin-
dependent kinases in tumor cells [7, 8], enhance the cytotoxic
effects of doxorubicin [9], and represent an efficient treatment
for psoriasis [10]. In a study of patients with head and neck
cancer, indirubins were found to reduce the mucosal damage
caused by radiation therapy [11, 12]. Indirubins inhibit DNA
synthesis during cell proliferation in the late-G1 and G2/M
phases by selectively inhibiting cyclin-dependent kinases
(CDK) [12, 13] by competing at the ATPase-binding site [8].
Indirubin inhibits the assembly of microtubules involved in
cell reproduction [14]. Its anti-inflammatory effects seem to
originate from its inhibition of interferon gamma [2].
Indirubin is a constituent of Indigofera tinctoria; the synthetic
form of indirubin was shown to have a similar effectiveness
against CML to that of natural indirubin [15–17]. Indirubin
also inhibits the growth of the human promyelocytic leukemia
cell line HL-60 [18] and human HT-29 colorectal cancer cells
[19], and it modulates the proliferation of keratinocytes in
patients with psoriasis [20]. Mitochondrial dysfunction due
to indirubin-3′-oximemay be an important mechanism for cell
cycle arrest in human neuroblastoma cells [21].
During the investigations reported in the present paper, the
inhibitory effects of ChEMBL474807 (1-(4-amino-1,2,5-
oxadiazol-3-yl)-5-(piperidin-1-ylmethyl)-N′-(pyridin-4-
ylmethylene)-1H-1,2,3-triazole-4-carbohydrazide) on two en-
zymes, namely glycogen synthase kinase-3β (GSK-3β) and
cyclin-dependent kinase-2 (CDK-2), were analyzed (see
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Fig. 1). The close resemblance of the amino acid sequences of
these two enzymes (with 25 % identity and 41 % similarity)
[22] proved that indirubin derivatives are inhibitors of both
enzymes [23]. This situation necessitates a search for selective
kinase-inhibiting compounds [24].
Methods
During the docking simulations, the crystal structures of
CDK-2 (PDB ID: 1E9H) [25] and GSK-3β (PDB ID: 1Q41)
were used [26], both of which were downloaded from the
Brookhaven Protein Database (PDB). Docking was realized
using a united-atom scoring function implemented in
AutoDock Vina [27]. Before the docking stage, all of the
water molecules were removed from the crystal structures of
the considered enzymes, as were all of the nonpolar hydrogen
atoms. All preparation steps were performed using the
AutoDock Tools software package. After determining the grid
box dimensions for each of the active sites considered, the
docking procedure was repeated ten times. The conformations
of the ligand ChEMBL474807 at the active sites of the
enzymes (obtained during the docking stage) were almost
identical, and reproduced the binding-site interactions ob-
served experimentally [25, 26, 28, 29].
A molecular dynamics procedure was applied to the struc-
ture of the complex of the CDK-2 or GSK-3β protein subunit
with the ligand ChEMBL474807, as obtained during the
docking procedure. The structure of the ligand structure was
characterized using Amber force-field parameters, and the
atomic charges were calculated according to the Merz–
Kollman scheme via the RESP procedure [30] at the HF/6-
31G* level. Each system was neutralized and immersed in a
periodic TIP3P water box. The systems considered were heat-
ed to 300 K during the initial 100 ps of MD simulation, while
the temperature was controlled by a Langevin thermostat [31].
Periodic boundary conditions and the SHAKE algorithm [32]
were then applied for 110 ns of molecular dynamics simula-
tion. The first 20 ns of this simulation time were used as an
equilibration interval; the next 90 ns of the trajectory were
used to analyze interactions between the subunits considered.
The energies of the interactions between the ligand and the
active site were characterized using the molecular mechanics/
Poisson–Boltzmann surface area (MMPBSA) method [33].
The AMBER 11 package [34] was used in all of the molecular
dynamics simulations. Structural analysis, including calcula-
tions of the hydrogen bonds present and the root-mean-square
deviations (RMSDs) of atomic positions, were performed
using the VMD package [35]. All of the RMSD calculations
for the ligand molecule and the amino acids at the active sites
were performed relative to the initial structure of the complex
obtained during the docking stage. Hydrogen atoms were ex-
cluded from those calculations.
Results
The proteins considered in this work, namely cyclin-
dependent kinase 2 (CDK-2) and glycogen synthase kinase-
3 (GSK-3β), exhibit high similarity in terms of the amino acid
sequences within their active sites. The mechanism for
inhibiting these enzymes has frequently been analyzed by
computational methods. One group of compounds that exhibit
high affinity for the ATP-binding pockets of the two kinases
considered here includes indirubin and its analogs [22, 23, 25,
26, 28, 29]. Existing studies indicate a significant role of hy-
drogen bonds in stabilizing the interactions of these enzymes
with ligands, with specific amino acids in each enzyme par-
ticipating in the hydrogen bonds [28, 29]. For cyclin-
dependent kinases, the most important roles in hydrogen-
bond creation are played by the amino acid residues GUA81
and LEU83; the former participates in one hydrogen bond
while the latter is involved in two [28]. Avery similar situation
was observed for glycogen synthase kinases, where a network
Fig. 1a–b The most important interactions observed between
ChEMBL474807 and the active sites in the enzymes CDK-2 (a) and
GSK-3β (b)
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of hydrogen bonds was created that involved ASP133 (one H-
bond) and VAL135 (two H-bonds) [28, 29].
During the docking stage of our investigations, we used the
molecule of the ligand ChEMBL474807 (Fig. 2). The nitro-
gen N6 and the hydrogens HN14 and HN15 were found to
participate in hydrogen bonds that stabilize complexes of this
ligand with kinases. After performing the docking procedure,
complexes of both kinases with ChEMBL474807 were ob-
tained. For both of the considered kinases, the ligand molecule
was observed to be stabilized by three hydrogen bonds (see
Fig. 1): for CDK2, these hydrogen bonds were GLU81(O)···
NH14(ligand), LEU 83(HN)···N6(ligand), and LEU83(O)···
HN15(ligand); for GSK 3β, the hydrogen bonds were
VAL135(O)···HN15(ligand), VAL135(NH)···N6(ligand), and
ASP133(O)···HN14(ligand). In both cases, the observed hy-
drogen bonds were consistent with existing findings for the
interactions that occur in the ATP-binding pockets of the con-
sidered kinases. The binding affinities for both complexes
were quite similar: −9.1 kcal/mol for CDK-2 and −10.1 kcal/
mol for GSK-3β. In both cases, the standard deviations for
these values did not exceed 0.1 kcal/mol.
The stabilities of the complexes obtained during the
docking stage were evaluated by performing molecular dy-
namics simulations. These computations yielded a large group
of conformations corresponding to the time evolution of
ChEMBL474807 at the active site of CDK-2 or GSK-3β.
The stabilities of the structures formed during the trajectories
in the simulations were evaluated by calculating their mean
RMSD (root-mean-square deviation) values. The graphs pre-
sented in Fig. 3 show the time evolutions of the RMSDs for
the ligand molecule and for all of the amino acids comprising
the ATP-binding pockets in both kinases. The RMSD values
Fig. 2 Structure of the ligand molecule ChEMBL474807; the labeled
atoms are involved in hydrogen bonds with amino acids from the active
sites of CDK-2 and GSK-3β
Table 1 Average RMSDs for the ligand and for the amino acids












RMSD 1.18 1.80 1.47 2.11
SD 0.18 0.21 0.19 0.25
SD standard deviation
Fig. 3 Variations in the RMSD values for the ligand and for the amino
acids of the active sites of CDK-2 and GSK-3β over the course of the
molecular dynamics simulation
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obtained led us to conclude that 20 ns of molecular dynamics
simulation are sufficient to achieve equilibration. Slightly
higher fluctuations in the RMSD value were seen for the
GSK3B complex, an observation confirmed by the average
values listed in Table 1. However, structural stabilization was
seen for both complexes.
The final 90 ns of the trajectories were used for structural
analysis. The structures of both ligand–protein complexes are
consolidated by various types of forces, the most important of
which are hydrogen bonds and hydrophobic interactions. The
results of molecular dynamics simulations confirmed the con-
clusions drawn from the docking results. All three hydrogen
bonds between ChEMBL474807 and amino acids (GLU81
and LEU83) in CDK-2 were present throughout the simula-
tion (Fig. 1a), although the strengths of these interactions var-
ied over time. The strength of a hydrogen bond can be gauged
from the distance between the donor and acceptor. In the ATP-
binding pocket, the most stable interaction was observed to be
LEU83(O)···HN15(ligand). In over 90% of the conformations
encountered during the simulation, the interaction between
these atoms was a strong or moderately strong hydrogen bond
(Table 2, Fig. 4). This amino acid (LEU83) also participates in
the moderately strong interaction LEU83(HN)···N6(ligand),
the length of which corresponded to a hydrogen bond in over
75 % of the conformations collected during the simulation.
The final interaction considered was GLU81(O)···
NH14(ligand). This interaction corresponded to a strong
hydrogen bond in some conformations, but to a moderately
strong H-bond in most conformations (70 %).
An important influence on the stability of each complex was
the coexistence of all three of the hydrogen bonds reported
above within the ATP-binding pocket, as illustrated in Fig. 5a,
b, and c for the active site of CDK2: all three plots show uni-
form concentric distributions, which confirms that all interac-
tions responsible for complex stabilization have uniform distri-
bution during whole simulation without any important fluctua-
tions indicating on conformational flexibility of analyzed sys-
tem. The hydrogen-bond length data suggest that most of the
conformations collected during the molecular dynamics simu-
lations are stabilized by at least one strong and two moderately
strong bonds; only a few conformations include weak hydrogen
bonds. These observations confirm the high stability of the
complexes obtained during the docking stage.
The next most important interactions involved in the stabili-
zation of the ligand at the active site of CDK-2 are those between
the aromatic phenylalanine rings andChEMBL474807. The data
collected (Fig. 6) indicate that, throughout the whole simulation,
the distances of these aromatic rings from ChEMBL474807 and
the relative orientations of the rings with respect to the ligand
permit the occurrence of stabilizing interactions. During most of
the simulation (PHE80: 70 %; PHE82: 85 % of the conforma-
tions), the distances between the two phenylalanine rings and the
aromatic system of the ligand did not exceed 4.5 Å, leading to
overlapping rings and stacking interactions in both cases.
Fig. 4a–b Distribution of the
lengths of hydrogen bonds
between ChEMBL474807 and
amino acids in the active site of
CDK-2 (a) or GSK-3β (b)
throughout the simulation time.
The hydrogen-bond lengths have
been binned into 0.25-Å intervals
(the length values shown repre-
sent the midpoints of the
intervals)
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Interactions of ChEMBL474807 with the second active
site, namely that of GSK-3β, also involve three hydrogen
bonds. VAL135 and ASP133 participate in these three H-
bonds (Fig. 1b). The most stable hydrogen bond is
ASP133(O)···HN14(ligand), which is present in more than
80 % of the conformations produced during the simulation.
While this bond was usually observed to be only moderately
strong, there were a non-negligible group of conformations in
which this interaction was strong (Table 2 and Fig. 4). The
next most important H-bond between ChEMBL474807 and
GSK-3β is VAL135(NH)···N6(ligand). This hydrogen bond
was found to be moderately strong in 65 % of the conforma-
tions; however, in about 20 % of the conformations, the dis-
tance between the atoms involved in this bond exceeded 3 Å,
which is too long for a hydrogen bond to be effective. The
third and weakest H-bond between ChEMBL474807 and
GSK-3β is VAL135(O)···HN15(ligand), observed in about
Fig. 6 Distribution of distances between ChEMBL474807 and two





Fig. 5a–f Three hydrogen bonds
occurred consistently in the
complex ChEMBL474807–
CDK-2, according to the
conformations collected during
the molecular dynamics
simulation of that complex, and
three different H-bonds occurred
consistently during the
corresponding simulation of the
complex ChEMBL474807–
GSK-3β. This figure presents
plots of one hydrogen-bond
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40 % of the conformations collected during the molecular
dynamics simulation. This H-bond was found to be either
moderately strong or weak. The plots shown in Fig. 5d, e,
and f confirm the previous observations made about the sta-
bilizing interactions of ChEMBL474807 with GSK-3β. The
coexistence of the two hydrogen bonds ASP133(O)···
HN14(ligand) and VAL135(NH)···N6(ligand) (Fig. 5f) was
found to ensure a stable complex. The position of the center
of the distribution and the shape of the distribution in each plot
shed light on the binding interactions considered. The shapes
of the distributions in Fig. 5d and e indicate that the
VAL135(O)···HN15(ligand) bond fluctuates markedly in
length during the simulation. In all of the charts (Fig. 5d, e,
and f), a minor fraction (∼15 %) of the conformations are
characterized by interaction distances of 5–6 Å. Interestingly,
the hydrogen bonds differed in their length fluctuations. In the
case of VAL135(O)···HN15, unrestricted fluctuations cover-
ing the full range of bond lengths were observed, whereas
stepwise changes in length were seen for the other two H-
bonds (these stepped changes in bond length probably relate
to changes in the conformation of the ligand ChEMBL474807
relative to the GSK-3β active site). These observations sug-
gest the possibility of a presence of another energetically fa-
vorable conformation of ligand in the enzyme active site. Two
hydrogen bonds, which formed between the ligand and oxy-
gen atoms of two amino acids: VAL95(O)···HN14(ligand) and
TYR94(OH)···N6(ligand), were observed. However analysis
of the hydrogen-bond length, recorded for these conforma-
tions, suggests weak character of these interactions.
The energetics of both complexes during molecular dynam-
ics simulation were analyzed. Gibbs free energy analysis was
performed using the molecular mechanics/Poisson–Boltzmann
surface area method. The enthalpy and entropy contributions to
the Gibbs free energy were calculated for each complex.
Average energetic values for the interaction between
ChEMBL474807 and CDK-2 and between ChEMBL474807
and GSK-3β are listed in Table 3. For the complex involving
GSK-3β, two independent calculations were done: first, the
dominant conformations of the ligand relative to the active site
were characterized; second, the less common conformations
were accounted for. The stabilizing interactions observedwithin
the complex of ChEMBL474807 with CDK-2 were confirmed
because their presence corresponded to the lowest value of the
Gibbs free energy. The ΔG values for the complex including
GSK-3β indicated a low affinity of the ligand for the active site,
especially in the second conformation analyzed.
Conclusions
Analysis of the properties of complexes formed by the ligand
ChEMBL474807 with the kinases CDK-2 and GSK-3β
Table 2 Length distributions of the most common hydrogen bonds that
occurred between ChEMBL474807 and selected amino acids from the
active sites of CDK-2 and GSK-3β in molecular dynamics simulations

































a .In the table, hydrogen-bond lengths have been binned into 0.25-Å
length intervals; each length listed under ‘Hydrogen-bond length’ repre-
sents the midpoint of a length interval
Table 3 Binding free energies (ΔG, kcal/mol) for the complex
ChEMBL474807—CDK-2 and the complex ChEMBL474807–GSK-
3β during MD simulations. ΔH and TΔS refer to the enthalpic and
entropic contributions to the Gibbs free energy, respectively
Energetic parameter CDK-2 GSK-3β (1)a GSK-3β (2)a
Value SD Value SD Value SD
ΔH −28.29 4.13 −26.01 3.92 −17.53 3.15
TΔS −10.29 4.94 −18.00 7.08 −23.73 4.89
ΔG −17.68 6.44 −8.00 8.09 6.20 5.82
For the complex involving GSK-3β, two independent calculations were
performed: first, the dominant conformations of the ligand relative to the
active site were characterized [GSK-3β (1)]; second, the less common
conformations were accounted for [GSK-3β (2)]
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revealed important differences between these complexes in
their structural and energetic properties. For both complexes,
conformations stabilized by hydrogen bonds (characteristic of
indirubin and its analogs) were observed during the docking
stage. However, the values obtained during molecular dynam-
ics simulations indicated substantial differences between the
behavior of the ligand ChEMBL474807 in the ATP-binding
pocket of CDK-2 and its behavior in the ATP-binding pocket
of GSK-3β; these differences were mainly in the occurrence
and strength of the hydrogen bonds between the ligand and
each kinase. For the complex between ChEMBL474807 and
the active site of CDK-2, the greatest contribution to the li-
gand–kinase binding derives from the heterocyclic part of the
ligand molecule, namely the atoms HN15 and N6. On the
other hand, for the complex between ChEMBL474807 and
the active site of GSK-3β, the heterocyclic part of the ligand
molecule is much less involved in the binding process. The
coexistence of all hydrogen bonds is a requirement for these
complexes to remain stable. The disappearance or significant
weakening of some of the H-bonds, as observed in the com-
plex with GSK-3β, may lead to structural distortions and con-
formational changes. The observed differences between the
complexes, which are related to differences in the frequency
of occurrence and strengths of particular hydrogen bonds as
well as in binding affinities, indicate that there is a higher
structural and energetic affinity of the ChEMBL474807 mol-
ecule for CDK-2 than for GSK-3β.
In conclusion, the structural and energetic data presented
here indicate a significant difference between the affinity of
ChEMBL474807 for CDK-2 and the aff in i ty of
ChEMBL474807 for GSK-3β.
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